These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 22489254)
21. The cutaneous manifestations are significantly related to cerebrovascular in a Serbian cohort of patients with Hughes syndrome. Stojanovich L; Djokovic A; Stanisavljevic N; Zdravkovic M Lupus; 2018 Apr; 27(5):858-863. PubMed ID: 29301476 [TBL] [Abstract][Full Text] [Related]
22. Association between non-thrombotic neurological and cardiac manifestations in patients with antiphospholipid syndrome. Stojanovich L; Kontic M; Smiljanic D; Djokovic A; Stamenkovic B; Marisavljevic D Clin Exp Rheumatol; 2013; 31(5):756-60. PubMed ID: 23899875 [TBL] [Abstract][Full Text] [Related]
23. Pandemic influenza immunization in primary antiphospholipid syndrome (PAPS): a trigger to thrombosis and autoantibody production? de Medeiros DM; Silva CA; Bueno C; Ribeiro AC; Viana Vdos S; Carvalho JF; Bonfa E Lupus; 2014 Nov; 23(13):1412-6. PubMed ID: 24961747 [TBL] [Abstract][Full Text] [Related]
32. The impact of antibody profile in thrombosis associated with primary antiphospholipid syndrome. da Silva Saraiva S; de Moraes Mazetto B; Quinteiro Tobaldine L; Pereira Colella M; Vinícius De Paula E; Annichinno-Bizzachi J; Andrade Orsi F Am J Hematol; 2017 Nov; 92(11):1163-1169. PubMed ID: 28762539 [TBL] [Abstract][Full Text] [Related]
33. A rarely seen syndrome in rehabilitation of hemiplegia: antiphospholipid antibody-negative Sneddon's syndrome. Akbal A; Kurtaran A; Selçuk B; Ersöz M; Akyüz M Rheumatol Int; 2010 Sep; 30(11):1489-91. PubMed ID: 19697034 [TBL] [Abstract][Full Text] [Related]
34. Lupus anticoagulant: a marker for stroke and venous thrombosis in primary Sjögren's syndrome. Pasoto SG; Chakkour HP; Natalino RR; Viana VS; Bueno C; Lianza AC; de Andrade JL; Neto ML; Fuller R; Bonfa E Clin Rheumatol; 2012 Sep; 31(9):1331-8. PubMed ID: 22692396 [TBL] [Abstract][Full Text] [Related]
35. [The clinical manifestations and thrombotic risk factors in primary antiphospholipid syndrome]. Zhao JL; Sun YD; Zhang Y; Xu D; Wang Q; Li MT; Zeng XF Zhonghua Nei Ke Za Zhi; 2016 May; 55(5):386-91. PubMed ID: 27143190 [TBL] [Abstract][Full Text] [Related]
36. Clinical, neurovascular and neuropathological features in Sneddon's syndrome. Marinho JL; Piovesan EJ; Leite Neto MP; Kotze LR; Noronha Ld; Twardowschy CA; Lange MC; Scola RH; Zétola VH; Nóvak EM; Werneck LC Arq Neuropsiquiatr; 2007 Jun; 65(2B):390-5. PubMed ID: 17665002 [TBL] [Abstract][Full Text] [Related]
37. Classification of Sneddon's syndrome. Schellong SM; Weissenborn K; Niedermeyer J; Wollenhaupt J; Sosada M; Ehrenheim C; Lubach D Vasa; 1997 Aug; 26(3):215-21. PubMed ID: 9286155 [TBL] [Abstract][Full Text] [Related]
39. [Clinical and analytical manifestations of primary antiphospholipid antibody syndrome]. Camps García MT; Gutiérrez Rueda A; Guil García M; Perelló-González Moreno I; García Portales R; Belmonte López A; de Rámon Garrido E An Med Interna; 1993 Dec; 10(12):576-82. PubMed ID: 8049321 [TBL] [Abstract][Full Text] [Related]
40. [Antiphospholipid syndrome (APS) primary (PAPS) and secondary (SAPS)]. Chwalińska-Sadowska H; Meissner M; Wudarski M; Zabek J; Wojciechowska B Pol Arch Med Wewn; 2006 May; 115(5):401-6. PubMed ID: 17195351 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]